FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Recruiting · NCT05304962 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-08-12 | NCT05304962 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Regor Pharmaceuticals Inc. | 3 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University | Atlanta | United States | 262 |
| Hem-Onc Associates of the Treasure Coast | Port Saint Lucie | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| New York Cancer and Blood Specialists | Port Jefferson Station | United States | 2 |
| University California, Los Angeles | Los Angeles | United States | 1 |
| University of California, San Diego | La Jolla | United States | 25 |
| Washington University School of Medicine | St Louis | United States | 895 |